Enzyme Replacement Therapy Market by Product, Disease and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

2.1. Key findings of the study
2.2. CXO perspective

3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five force analysis
3.4. Top player positioning, 2020
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in the prevalence of rare diseases
3.5.1.2. Availability of a wide range of enzyme replacement therapy
3.5.1.3. Increasing Government initiatives for rare diseases
3.5.2. Restraint
3.5.2.1. High cost of the treatment
3.5.3. Opportunity
3.5.3.1. New developments in therapies coupled with growing opportunities in emerging market
3.5.4. Impact analysis
3.6. COVID-19 impact analysis on the Enzyme replacement therapy market

4.1. Overview
4.1.1. Market size and forecast
4.2. Agalsidase Beta
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.2.1. Agalsidase beta by end users
4.2.3. Market analysis, by country
4.3. Imiglucerase
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.2.1. Imiglucerase by end users
4.3.3. Market analysis, by country
4.4. Velaglucerase alfa
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.2.1. Velaglucerase alfa by end users
4.4.3. Market analysis, by country
4.5. Idursulfase
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.2.1. Idursulfase by end users
4.5.3. Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.6. Galsulfase
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.2.1. Galsulfase by end users
4.6.3. Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.7. Laronidase
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.2.1. Laronidase by end users
4.7.3. Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis
4.8. Others
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.2.1. Others by end users
4.8.3. Market analysis, by country
Source: Primary & Secondary Research and AMR Analysis

5.1. Overview
5.1.1. Market size and forecast
5.2. Gaucher disease
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Fabry Disease
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Pompe Disease
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Mucopolysaccharidosis
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Exocrine pancreatic insufficiency EPI
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Others
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country

6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Infusion Centers & Home Healthcare Setting
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. North America enzyme replacement therapy market, by product
7.2.3. North America infection surveillance services market, by disease type
7.2.4. North America infection surveillance services market, by end user
7.2.5. Market size and forecast, by country
7.2.5.1. U. S. Enzyme replacement therapy market, by product
7.2.5.2. U. S. Enzyme replacement therapy market, by disease
7.2.5.3. U. S. Enzyme replacement therapy market, by end user
7.2.5.4. Canada Enzyme replacement therapy market, by product type
7.2.5.5. Canada Enzyme replacement therapy market, by disease type
7.2.5.6. Canada Enzyme replacement therapy market, by end user
7.2.5.7. Mexico Enzyme replacement therapy market, by product
7.2.5.8. Mexico Enzyme replacement therapy market, by disease type
7.2.5.9. Mexico Enzyme replacement therapy market, by end user
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Europe infection surveillance services market, by product
7.3.3. Europe infection surveillance services market, by disease type
7.3.4. Europe infection surveillance services market, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. Germany Enzyme replacement therapy market, by product
7.3.5.2. Germany Enzyme replacement therapy market, by disease type
7.3.5.3. Germany Enzyme replacement therapy market, by end user
7.3.5.4. France Enzyme replacement therapy market, by product
7.3.5.5. France Enzyme replacement therapy market, by disease type
7.3.5.6. France Enzyme replacement therapy market, by end user
7.3.5.7. UK Enzyme replacement therapy market, by product
7.3.5.8. UK Enzyme replacement therapy market, by disease type
7.3.5.9. UK Enzyme replacement therapy market, by end user
7.3.5.10. Italy Enzyme replacement therapy market, by product
7.3.5.11. Italy Enzyme replacement therapy market, by disease type
7.3.5.12. Italy Enzyme replacement therapy market, by end user
7.3.5.13. Spain Enzyme replacement therapy market, by product
7.3.5.14. Spain Enzyme replacement therapy market, by disease type
7.3.5.15. Spain Enzyme replacement therapy market, by end user
7.3.5.16. Rest of Europe Enzyme replacement therapy market, by product
7.3.5.17. Rest of Europe Enzyme replacement therapy market, by disease type
7.3.5.18. Rest of Europe Enzyme replacement therapy market, by end user
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Asia-Pacific infection surveillance services market, by product
7.4.3. Asia-Pacific infection surveillance services market, by disease type
7.4.4. Asia-Pacific infection surveillance services market, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan Enzyme replacement therapy market, by product
7.4.5.2. Japan Enzyme replacement therapy market, by disease type
7.4.5.3. Japan Enzyme replacement therapy market, by end user
7.4.5.4. China Enzyme replacement therapy market, by product
7.4.5.5. China Enzyme replacement therapy market, by disease type
7.4.5.6. China Enzyme replacement therapy market, by end user
7.4.5.7. Australia Enzyme replacement therapy market, by product
7.4.5.8. Australia Enzyme replacement therapy market, by disease type
7.4.5.9. Australia Enzyme replacement therapy market, by end user
7.4.5.10. India Enzyme replacement therapy market, by product
7.4.5.11. India Enzyme replacement therapy market, by disease type
7.4.5.12. India Enzyme replacement therapy market, by end user
7.4.5.13. South Korea Enzyme replacement therapy market, by product
7.4.5.14. South Korea Enzyme replacement therapy market, by disease type
7.4.5.15. South Korea Enzyme replacement therapy market, by end user
7.4.5.16. Rest of Asia-Pacific Enzyme replacement therapy market, by product
7.4.5.17. Rest of Asia-Pacific Enzyme replacement therapy market, by disease type
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. LAMEA infection surveillance services market, by product
7.5.3. LAMEA infection surveillance services market, by disease type
7.5.4. LAMEA infection surveillance services market, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil Enzyme replacement therapy market, by product
7.5.5.2. Brazil Enzyme replacement therapy market, by disease type
7.5.5.3. Brazil Enzyme replacement therapy market, by end user
7.5.5.4. Saudi Arabia Enzyme replacement therapy market, by product
7.5.5.5. Saudi Arabia Enzyme replacement therapy market, by disease type
7.5.5.6. Saudi Arabia Enzyme replacement therapy market, by end user
7.5.5.7. South Africa Enzyme replacement therapy market, by product
7.5.5.8. South Africa Enzyme replacement therapy market, by disease type
7.5.5.9. South Africa Enzyme replacement therapy market, by end user
7.5.5.10. Rest of LAMEA Enzyme replacement therapy market, by product
7.5.5.11. Rest of LAMEA Enzyme replacement therapy market, by disease type
7.5.5.12. Rest of LAMEA Enzyme replacement therapy market, by end user

8.1. ABBVIE INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. ASTRAZENECA PLC (ASTRAZENECA)
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. BioMarin Pharmaceutical Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. Chiesi Farmaceutici S. P. A
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Digestive Care, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Product portfolio
8.6. Leadiant Biosciences, Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments
8.7. NESTLE S. A. (Nestlé Health Science S. A.)
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. PFIZER, INC.
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. SANOFI S. A.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Takeda Pharmaceutical Company Limited
8.10.1. Company overview
8.10.2. Operating business segments
8.10.3. Product portfolio
Takeda Pharmaceutical. offers the following enzyme replacement therapies:
8.10.4. Business performance
8.10.5. Key strategic moves and developments

TABLE 01. ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 02. AGALSIDASE BETA ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 03. ALGASIDAE BETA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 04. IMIGLUCERASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 05. IMIGLUCERASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 06. ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 07. VELAGLUCERASE ALFA MARKET, BY END USER, 2020-2030($MILLION)
TABLE 08. IDURSULFASE MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 09. IDURSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 10. ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11. GALSULFASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 12. ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 13. LARONIDASE MARKET, BY END USER, 2020-2030($MILLION)
TABLE 14. ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 15. OTHERS MARKET, BY END USER, 2020-2030($MILLION)
TABLE 16. ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 17. GAUCHER DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18. FABRY DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 19. POMPE DISEASE ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 20. MUCOPOLYSACCHARIDOSIS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 21. EXOCRINE PANCREATIC INSUFFICIENCY ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 22. OTHERS ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 23. ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 24. ENZYME REPLACEMENT THERAPY MARKET FOR HOSPITALS, BY REGION, 2020-2030 ($MILLION)
TABLE 25. INFUSION CENTERS & HOME HEALTHCARE SETTING ENZYME REPLACEMENT THERAPY MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 26. ENZYME REPLACEMENT THERAPY MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 27. NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 28. NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 29. NORTH AMERICA INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 30. NORTH AMERICA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 31. U.S. ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 32. U.S. ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE, 2020-2030
TABLE 33. U.S. ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 34. CANADA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 35. CANADA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 36. CANADA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 37. MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 38. MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 39. MEXICO ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 40. EUROPE INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41. EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 42. EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 43. EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 44. GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 45. GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 46. GERMANY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 47. FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 48. FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 49. FRANCE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 50. UK ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 51. UKENZYME REPLACEMENT THERAPY MARKET, BY INJURY TYPE, 2020-2030
TABLE 52. UK ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 53. ITALY ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 54. ITALY ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 55. ITALY ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 56. SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 57. SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 58. SPAIN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 59. REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 60. REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 61. REST OF EUROPE ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 62. ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 63. ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 64. ASIA-PACIFIC INFECTION SURVEILLANCE SERVICES MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 65. ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 66. JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 67. JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 68. JAPAN ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 69. CHINA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 70. CHINA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 71. CHINA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 72. AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 73. AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 74. AUSTRALIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 75. INDIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 76. INDIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 77. INDIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 78. SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 79. SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 80. SOUTH KOREA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 81. REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 82. REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 83. REST OF ASIA-PACIFIC ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 84. LAMEA INFECTION SURVEILLANCE SERVICES MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 85. LAMEA INFECTION SURVEILLANCE SERVICES MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 86. LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030 ($MILLION)
TABLE 87. LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 88. BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 89. BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 90. BRAZIL ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 91. SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 92. SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 93. SAUDI ARABIA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 94. SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 95. SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 96. SOUTH AFRICA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 97. REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY PRODUCT, 2020-2030
TABLE 98. REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY DISEASE TYPE, 2020-2030
TABLE 99. REST OF LAMEA ENZYME REPLACEMENT THERAPY MARKET, BY END USER, 2020-2030
TABLE 100. ABBVIE INC: COMPANY SNAPSHOT
TABLE 101. ABBVIE INC: OPERATING SEGMENTS
TABLE 102. ABBVIE INC: PRODUCT TYPE PORTFOLIO
TABLE 103. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 104. ASTRAZENECA: OPERATING SEGMENTS
TABLE 105. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 106. BIOMARIN: COMPANY SNAPSHOT
TABLE 107. BIOMARIN: OPERATING SEGMENTS
TABLE 108. BIOMARIN: PRODUCT PORTFOLIO
TABLE 109. CHIESI FARMACEUTICI.: COMPANY SNAPSHOT
TABLE 110. CHIESI FARMACEUTICI: OPERATING SEGMENTS
TABLE 111. MERCK: PRODUCT TYPE PORTFOLIO
TABLE 112. DIGESTIVE CARE: COMPANY SNAPSHOT
TABLE 113. SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 114. LEADIANT BIOSCIENCES: COMPANY SNAPSHOT
TABLE 115. LEADIANT BIOSCIENCES: PRODUCT TYPE PORTFOLIO
TABLE 116. NESTLE: COMPANY SNAPSHOT
TABLE 117. NESTLE: OPERATING SEGMENTS
TABLE 118. NESTLE: PRODUCT PORTFOLIO
TABLE 119. PFIZER INC: COMPANY SNAPSHOT
TABLE 120. PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 121. SANOFI: COMPANY SNAPSHOT
TABLE 122. SANOFI: OPERATING SEGMENTS
TABLE 123. SANOFI: PRODUCT TYPE PORTFOLIO
TABLE 124. TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 125. BIODIEM: OPERATING SEGMENTS
TABLE 126. TAKEDA PHARMACEUTICAL: PRODUCT PORTFOLIO

FIGURE 01. ENZYME REPLACEMENT THERAPY MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021 (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07. MODERATE BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE THREAT OF SUBSTITUTES
FIGURE 09. MODERATE THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING, 2020
FIGURE 12. IMPACT ANALYSIS
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY MEDICATION MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ENZYME REPLACEMENT THERAPY DEVICES MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 25. COMPARATIVE SHARE ANALYSIS OF INDIRECT ENZYME REPLACEMENT THERAPY MARKET, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 26. COMPARATIVE ANALYSIS OF ENZYME REPLACEMENT THERAPY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 27. COMPARATIVE ANALYSIS OF ENZYME REPLACEMENT THERAPY MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 28. ABBVIE INC: REVENUE, 2018-2020 ($MILLION)
FIGURE 29. ABBVIE INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 30. ASTRAZENECA: REVENUE, 2018-2020 ($MILLION)
FIGURE 31. ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32. ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 33. BIOMARIN: REVENUE, 2017-20219 ($MILLION)
FIGURE 34. BIOMARIN: REVENUE SHARE BY REGION, 2019 (%)
FIGURE 35. CHIESI FARMACEUTICI: REVENUE, 2018-2020 ($MILLION)
FIGURE 36. CHIESI FARMACEUTICI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37. NESTLE: REVENUE, 2018-2020 ($MILLION)
FIGURE 38. NESTLE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39. NESTLE: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
FIGURE 40. PFIZER INC: REVENUE, 2018-2020 ($MILLION)
FIGURE 41. PFIZER INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42. SANOFI: REVENUE, 2018-2020 ($MILLION)
FIGURE 43. SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44. SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 45. TAKEDA PHARMACEUTICAL: REVENUE, 2018-2020 ($MILLION)
FIGURE 46. TAKEDA PHARMACEUTICAL: REVENUE SHARE BY REGION, 2020 (%)